PBE News and Press, Invesco Dynamic Biotech & Genome From 03/19/21

Wall Street usually prices in events before they happen, and that is as true for Invesco Dynamic Biotech & (NYSE: PBE) as it is for any other company.  If news is anticipated, and investors want to know what to expect, a simple review of the stock's price action is one of the b...

Influential Investors can create defining moments in a stock's price, by simply making large buy and sell decisions, and Invesco Dynamic Biotech & (NYSE: PBE) is no exception.  Pivot points in a chart pattern are often created by these events, and as we have learned this does n...

A tell is a precursor of a stock's next move, and investors in Invesco Dynamic Biotech & (NYSE: PBE) look for these indicators all the time.  the good news is, tells are there for investors to see every day. For example, we have provided this data for PBE in the trading pl...

Some people say that timing does not matter, but it does.  If you were to buy Invesco Dynamic Biotech & (NYSE: PBE) at a high, see it fall, and not be able to buy more on the dip like the big boys can, that would be troubling.  Over time, Stock Traders Daily has found a wa...

Risk assets continued their historic run last week with EM equities and commodities leading the way. Bonds sold off as the 10-year Treasury note yield broke above 1.20% for the first time since the lows last spring. The 10-year TIPS yield closed the week at 1.02%, near the all-tim...

After a dramatic year of volatility, the U.S. stock market ended 2020 at record highs. Can this momentum continue this year? ESG investments clearly outperformed in 2020. 2021 should be a year of much better cash flow for companies. For further details see: A Stock Picke...

2020 was a busy year for global healthcare with unprecedented efforts to develop vaccines, treatments, and diagnostics for COVID-19. Deal flow in the sector continued to gain momentum in 2020, with M&A transactions and product licensing deals totalling five-year highs as large-cap...

The year 2021 is going to be one of radical uncertainty just because there is so much that is unknown about the pandemic, the economy, government policy, etc. The year 2020 was dominated by three things: the pandemic, the Fed's easy monetary policy, and bifurcation of the society, wit...

Recent positive developments in COVID-19 vaccines have spurred a wave of market exuberance, lifting share prices of biotech companies at the forefront of the vaccine race. COVID-19 and the urgency to find a cure have opened up opportunities, making the biotech sector a prospective spa...

The pharmaceutical market reached a value of US$1.25 trillion in 2019, according to Statista data , up from US$887 billion in 2010. By 2024, that value is is expected to increase further to an estimated US$1.59 billion. Experienced and novice investors alike may want to consider...